Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Stock Has Average Price Target of $22.43

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) has been assigned an average recommendation of “Moderate Buy” from the eleven analysts that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, six have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $22.43.

ARCT has been the subject of a number of research analyst reports. Citigroup raised shares of Arcturus Therapeutics from a “neutral” rating to a “buy” rating and upped their price target for the stock from $8.00 to $20.00 in a research note on Thursday, September 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Arcturus Therapeutics in a research report on Friday, July 17th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arcturus Therapeutics in a research note on Thursday, September 24th. BTIG Research dropped their price target on Arcturus Therapeutics from $23.00 to $20.00 and set a “buy” rating on the stock in a research report on Thursday, September 24th. Finally, Wall Street Zen downgraded Arcturus Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, October 4th.

Arcturus Therapeutics Trading Up 0.8%

Shares of NASDAQ:ARCT opened at $12.87 on Tuesday. The firm’s 50 day moving average is $12.59 and its two-hundred day moving average is $9.26. The firm has a market capitalization of $365.77 million, a P/E ratio of -3.89 and a beta of 2.48. Arcturus Therapeutics has a 52 week low of $5.50 and a 52 week high of $24.17.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its quarterly earnings data on Friday, August 7th. The biotechnology company reported ($0.84) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.00) by $0.16. Arcturus Therapeutics had a negative return on equity of 46.54% and a negative net margin of 317.62%.The business had revenue of $2.96 million during the quarter, compared to the consensus estimate of $3.11 million. Analysts predict that Arcturus Therapeutics will post -3.48 EPS for the current year.

Institutional Investors Weigh In On Arcturus Therapeutics

A number of institutional investors have recently modified their holdings of ARCT. Green Alpha Advisors LLC grew its stake in shares of Arcturus Therapeutics by 7.9% in the 3rd quarter. Green Alpha Advisors LLC now owns 29,234 shares of the biotechnology company’s stock valued at $400,000 after purchasing an additional 2,143 shares during the period. Versant Capital Management Inc grew its holdings in Arcturus Therapeutics by 648.6% during the third quarter. Versant Capital Management Inc now owns 3,032 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 2,627 shares during the period. Hsbc Holdings PLC grew its holdings in shares of Arcturus Therapeutics by 7.7% in the 2nd quarter. Hsbc Holdings PLC now owns 56,895 shares of the biotechnology company’s stock valued at $394,000 after buying an additional 4,070 shares during the period. Two Sigma Securities LLC bought a new stake in shares of Arcturus Therapeutics in the second quarter worth about $80,000. Finally, ADAR1 Capital Management LLC bought a new stake in Arcturus Therapeutics during the 1st quarter worth approximately $116,000. Institutional investors and hedge funds own 94.54% of the company’s stock.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc is a biotechnology company focused on developing medicines based on messenger RNA (mRNA) and other RNA technologies. Headquartered in San Diego, California, the company uses its proprietary LUNAR lipid-mediated delivery platform and STX self-amplifying mRNA technology to design and deliver RNA-based therapeutics and vaccines.

The company’s research and development activities address rare diseases, infectious diseases, respiratory conditions and other areas of significant unmet medical need.